Lupin saw the highest growth of 99% in patent filings and 299% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 59% and grants by 19%. GlobalData’s DataBook provides a comprehensive analysis of Lupin‘s patent filings and grants. Buy the databook here.
Lupin has been focused on protecting inventions in United States(US) with four publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 20% grants. The United States(US), South Korea(KR), Denmark(DK), and European Patent Office(EPO) patent Office are among the top ten patent offices where Lupin is filings its patents. Among the top granted patent authorities, Lupin has 20% of its grants in United States(US) and 20% in Finland(FI).
Patents related to climate change lead Lupin's portfolio
Lupin has the highest number of patents in climate change. For climate change, nearly 100% of patents were filed and no patents were granted in Q4 2023.
Bacterial vaginosis related patents lead Lupin portfolio followed by amoebic infections, and giardiasis
Lupin has highest number of patents in bacterial vaginosis followed by amoebic infections, giardiasis, viral infections, and mobiles, hand-helds, pdas, smartphones.
For comprehensive analysis of Lupin's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.